Otonomy, Inc. (OTIC)
| Market Cap | 137.58M |
| Revenue (ttm) | 203,000 |
| Net Income (ttm) | -45.18M |
| Shares Out | 52.32M |
| EPS (ttm) | -0.98 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 16 |
| Last Price | $2.43 |
| Previous Close | $2.36 |
| Change ($) | 0.07 |
| Change (%) | 2.97% |
| Day's Open | 2.38 |
| Day's Range | 2.36 - 2.46 |
| Day's Volume | 204,102 |
| 52-Week Range | 2.01 - 6.98 |
SAN DIEGO, June 15, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the initia...
Otonomy Inc (NASDAQ: OTIC) may have hit a snag with the development of its lead ear disorder candidate Otividex. Still, the company is trumpeting an early win for a gene therapy designed to treat congen...
OTO-825 administration rescues hearing and cochlear damage in two preclinical models of congenital hearing loss caused by GJB2 deficiency OTO-825 administration rescues hearing and cochlear damage in tw...
Conference call and webcast today at 4:30 p.m. ET
SAN DIEGO, May 04, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will rep...
AAV-mediated gene therapy rescues hearing and cochlear damage in two preclinical models of congenital hearing loss caused by GJB2 deficiency AAV-mediated gene therapy rescues hearing and cochlear damage...
SAN DIEGO, April 19, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the closi...
SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the prici...
SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that it h...
SAN DIEGO, April 06, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its parti...
SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the prese...
Investors need to pay close attention to Otonomy (OTIC) stock based on the movements in the options market lately.
SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that manag...
Otonomy Inc (NASDAQ: OTIC) has reported topline data from Phase 3 trial evaluating OTIVIDEX in patients with Ménière's disease. It is an inner ear disorder that causes episodes of vertigo (spinning) and...
SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that the P...
SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced multiple p...
Conference call and webcast today at 4:30 p.m. ET
SAN DIEGO, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will re...
OTIC failed a phase 3 trial and fell from $20 to $5, and hasn't recovered since despite succeeding in another phase 3. A tiebreaker third phase 3 is ongoing with data by 1Q2021.
SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that manag...
SAN DIEGO, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced positive t...
Otonomy (OTIC) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today provided updates reg...
SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that manag...
Otonomy, Inc. (OTIC) CEO David Weber on Q3 2020 Results - Earnings Call Transcript
Otonomy (OTIC) delivered earnings and revenue surprises of 12.00% and -54.55%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Otonomy, Inc. (OTIC) CEO David Weber On Q3 2020 Results - Quick Version Earnings Call Transcript
Shares of Otonomy (NASDAQ:OTIC) were flat after the company reported Q3 results. Quarterly Results Earnings per share were up 33.33% over the past year to ($0.22), which beat the estimate of ($0.24).
Conference call and webcast today at 4:30 p.m. ET
SAN DIEGO, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will re...
SAN DIEGO, Oct. 02, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the comple...
Investors need to pay close attention to Otonomy (OTIC) stock based on the movements in the options market lately.
SAN DIEGO, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that ma...
Otonomy, Inc. (OTIC) CEO David Weber on Q2 2020 Results - Earnings Call Transcript
Otonomy (OTIC) delivered earnings and revenue surprises of -2.78% and -92.06%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Compound has potential to benefit patients with severe hearing loss Compound has potential to benefit patients with severe hearing loss
Webcast and Conference Call to be Held at 5 p.m. EDT on August 4, 2020 Webcast and Conference Call to be Held at 5 p.m. EDT on August 4, 2020
SAN DIEGO, July 13, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the clos...
Otonomy (OTIC) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
SAN DIEGO, July 09, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the pric...
SAN DIEGO, July 08, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that it ...
Otonomy (NASDAQ: OTIC) shares are trading higher on Tuesday. The company reported results from its Phase 1/2 clinical trial of OTO-313 in patients with Tinnitus demonstrated a higher proportion of respo...
SAN DIEGO, July 06, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced positive...
Management will review the OTIVIDEX statistical analysis plan update together with the positive top-line OTO-313 Phase 1/2 trial results during a conference call today at 4:30 p.m. ET Management will re...
Conference call and webcast today at 4:30 p.m. ET
Otonomy (OTIC) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
SAN DIEGO, June 11, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that Dav...
SAN DIEGO, June 10, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that due...
Conference call to review status of clinical trials and timing to results to be held in June Conference call to review status of clinical trials and timing to results to be held in June
SAN DIEGO, April 09, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today provided a busin...
About OTIC
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. It also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone that has completed Phase III clinical trial for the treatment of Ménière's disease; OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which has completed Phase I/II clinica... [Read more...]
| Industry Biotechnology | IPO Date Aug 13, 2014 |
| CEO David Weber | Employees 56 |
| Stock Exchange NASDAQ | Ticker Symbol OTIC |
Financial Performance
In 2020, Otonomy's revenue was $273,000, a decrease of -54.50% compared to the previous year's $600,000. Losses were -$44.73 million, 0.13% more than in 2019.
Analyst Forecasts
According to 5 analysts, the average rating for Otonomy stock is "Strong Buy." The 12-month stock price forecast is 5.63, which is an increase of 131.69% from the latest price.